Potassium Channel Opener Having Benzofuroindole Skeleton

• US 20080194837A1
• Filed: 03/10/2006
• Published: 08/14/2008
• Est. Priority Date: 03/10/2005
• Status: Active Grant

• Current Assignee: Anygen Co., Ltd.
• Original Assignee: Anygen Co., Ltd.
• Inventors: Kim, Yong-Chul, Park, Chul-Seung, Ha, Tal-Soo
• Granted Patent: US 7,812,177 B2
• Time in Patent Office: Days
• US Class Current: 548/421
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 3/12 for electrolyte homeostasis
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07D 491/04 Ortho-condensed systems

Abstract

The object of the present invention is to provide a potassium channel opener having benzofuroindole skeleton representing the following formula (I) wherein, R₁ is hydrogen, R₂ is CF₃, R₃ is COOH, R₄ is hydrogen, R₅ is hydrogen or chloride and R₆ is hydrogen or chloride.

Claims

1. A potassium channel opener having benzofuroindole skeleton representing the following formula (I).

2. The potassium channel opener having benzofuroindole skeleton according to claim 1, wherein R₁ is hydrogen, R₂ is CF₃, R₃ is COOH, R₄ is hydrogen, R₅ is hydrogen and R₆ is hydrogen.

3. The potassium channel opener having benzofuroindole skeleton according to claim 1, wherein R₁ is hydrogen, R₂ is CF₃, R₃ is COOH, R₄ is hydrogen, R₅ is hydrogen and R₆ is chloride.

4. The potassium channel opener having benzofuroindole skeleton according to claim 1, wherein R₁ is hydrogen, R₂ is CF₃, R₃ is COOH, R₄ is hydrogen, R₅ is chloride and R₆ is hydrogen.

5. A process for preparing a potassium channel opener having benzofuroindole skeleton representing the following formula (I), which comprises the steps of:

i) preparing compound of formula (III) by reacting and condensing salicylic acid derivatives represented by formula (II) as starting material